Igor Bilinsky
Chief Operating Officer presso IOVANCE BIOTHERAPEUTICS, INC.
Patrimonio netto: 563 545 $ in data 31/03/2024
Profilo
Igor P. Bilinsky ricopre la posizione di direttore operativo di Iovance Biotherapeutics, Inc. In precedenza il dott. Bilinsky ha occupato la posizione di amministratore delegato presso Androclus Therapeutics, Inc., VP-Business Development & Special Operations presso Halozyme Therapeutics, Inc., Principal presso The Boston Consulting Group, Inc, Chief Operating Officer & Senior Vice President di AmpliPhi Biosciences Corp., Head-Research & Development di Symyx Technologies, Inc., Senior Vice President-Corporate Development di Vical, Inc. e Senior VP-Special Operations, GM-Immuno & Oncology di Ignyta, Inc. Igor P. Bilinsky si è laureato all'Istituto di Fisica e Tecnologia di Mosca e ha conseguito un dottorato al Massachusetts Institute of Technology.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
15/04/2024 | 38 026 ( 0.01% ) | 563 545 $ | 31/03/2024 |
Posizioni attive di Igor Bilinsky
Società | Posizione | Inizio |
---|---|---|
IOVANCE BIOTHERAPEUTICS, INC. | Chief Operating Officer | 15/03/2021 |
Precedenti posizioni note di Igor Bilinsky
Società | Posizione | Fine |
---|---|---|
ONCTERNAL THERAPEUTICS, INC. | Corporate Officer/Principal | 01/03/2021 |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | Chief Operating Officer | 14/01/2019 |
IGNYTA INC | Corporate Officer/Principal | 01/01/2017 |
HALOZYME THERAPEUTICS, INC. | Corporate Officer/Principal | 01/01/2010 |
Androclus Therapeutics, Inc. | Chief Executive Officer | 01/01/2007 |
Formazione di Igor Bilinsky
Massachusetts Institute of Technology | Doctorate Degree |
Moscow Institute of Physics & Technology | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 3 |
---|---|
HALOZYME THERAPEUTICS, INC. | Health Technology |
IOVANCE BIOTHERAPEUTICS, INC. | Health Technology |
ONCTERNAL THERAPEUTICS, INC. | Health Technology |
Aziende private | 6 |
---|---|
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | Health Technology |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | Health Technology |
Symyx Technologies, Inc.
Symyx Technologies, Inc. Packaged SoftwareTechnology Services Symyx Technologies, Inc. develops and applies high-throughput experimentation to the discovery of materials for chemical and petrochemical, pharmaceutical development, electronics, consumer goods and automotive customers. The company works together with companies seeking to transform their search for better products and processes through research collaborations and Discovery Tools sales and the license of materials, intellectual property and software. The company was incorporated in February 1999 and is headquartered in Sunnyvale, CA. | Technology Services |
The Boston Consulting Group, Inc.
The Boston Consulting Group, Inc. Miscellaneous Commercial ServicesCommercial Services The Boston Consulting Group, Inc. engages in the provision of management consulting services. It specializes in automotive and mobility; biopharmaceuticals; consumer products; education; oil and gas; power and utilities; engineered products and infrastructure; financial institutions; and health care payers, providers, and services. It offers big data and advanced analytics; change management; client learning and enablement; and corporate development and financial services. The company was founded by Bruce Doolin Henderson in 1963 and is headquartered in Boston, MA. | Commercial Services |
Androclus Therapeutics, Inc. | |
Ignyta, Inc.
Ignyta, Inc. BiotechnologyHealth Technology Ignyta, Inc. operates as a medicine biotechnology company. The firm engages in the discovering, acquiring, developing and commercializing targeted new drugs for cancer patients. The company was founded by Jonathan E. Lim on September 13, 2011 and is headquartered in South San Francisco, CA. | Health Technology |
- Borsa valori
- Insiders
- Igor Bilinsky